Digital health start-ups worldwide may apply for a digital health solutions orientated mentoring programme based in Berlin.
Successful start-ups may receive the following support:
- Mentoring and coaching from Bayer Executives.
- Financial support worth €50,000.
- Networking opportunities and access to Bayer Experts.
- The use of office space for 100 days.
The Grants4Apps Accelerator is administered by Bayer Global, a Life Science company that is committed to finding solutions to major contemporary challenges. The Grants4Apps Accelerator is a Berlin based mentoring programme intended to support and develop digital health start-ups.
Information regarding any restrictions that may apply has not been given. Interested parties should contact the funding provider directly for further details.
Applications are welcome from legal entities or persons from anywhere in the world as long as they are over the age of 18. These applicants should be in the start-up stage. Bayer employees are also encouraged to make a submission.
Information regarding match funding has not been stipulated. Interested parties should contact the funding provider directly for further details.
Funding is intended to support the development of relevant digital health solutions.
For 2017, there will be a focus upon digital health solutions that address the following healthcare and life sciences' challenges:
- Clinical trials.
- Identifying and recruiting patients for clinical trials.
- Making improvements to the patient experience during clinical trials.
- Developing mobile platforms for patients to report health condition parameters.
- Improving adherence within clinical trials or within real life.
- Data analysis.
- Data analysis tools that systematically identify competitor Research & Development activities.
- Deep Learning Research Services for the purposes of health and life science data.
- The transformation of Electronic Health Records (EHR) data in order to analyse data sets.
- Analysing drug labels, such as patient information leaflets, in order to generate new insights.
- Implementing prediction algorithms in hospital information systems.
- Monitoring chronic kidney disease (CKD).
- Diagnosing acute kidney injury.
- Women's health.
- Developing early non-invasive diagnosis of endometriosis.
- Improving the identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
- Improving adherence for an oral pulmonary hypertension treatment.
- Innovative, efficient concepts for training members of staff to use a drug and device combination product within an intensive care unit setting.
Additionally, this programme is also open for innovative digital health solutions that are directed at helping healthcare providers or patients as well as products that are dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.
The next deadline for submissions is 31 May 2017.
Interested parties should submit their application using the online submission form
More than one project may be submitted and one submission may be made for each project proposal. Submissions should be written in English and the programme itself will be held in English.
Over 100 Bayer experts are involved within the judging process and will be taking into account the following criteria:
- Company maturity.
- Existing product prototypes.
- The team.
- The applicants fit with Bayer's areas of expertise.
A maximum of five start-ups will be chosen. The evaluation stage will take place from 6- 30 June 2017. A decision will be made on 1 July 2017.